Half of adalimumab patients did not give consent for biosimilar switch, survey reveals

Of almost 900 patients switched from Humira to biosimilar adalimumab, 53% reported that they were not asked for their consent.
Pre-filled syringe of Humira (adalimumab)
Overall, 34% of respondents said they were “not at all satisfied” with their biosimilar adalimumab after being switched from Humira

Martin Shields / Alamy Stock Photo

More than half of people with immune-mediated inflammatory diseases who were switched from Humira (adalimumab; AbbVie) to biosimilar adalimumab say they were not asked for their consent prior to the switch, a study has found.

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Last updated